Walgreens’ Ed Cohen wins Innovative Pharmacy Practice Award
SPRINGFIELD, Ill. The Illinois Pharmacists Association presented Ed Cohen, director of RDUR clinical operations at Walgreens Health Initiatives, with Elan Biopharmaceuticals’ Innovative Pharmacy Practice Award
A longtime member of the American Pharmacists Association, Cohen has served as chair of the administrative section of APhA’s Academy of Pharmacy Practice and Management. He also currently serves on the board of directors of the IPhA.
“Cohen received the Innovative Pharmacy Practice Award because of his strong influence on the pharmacists he has managed,” the IPhA stated. “His efforts in implementing pharmaceutical care in a chain/community pharmacy setting have been well noted and recognized. He has been an active proponent of the Ten City Challenge, a program initiated by the APhA Foundation, which expands the diabetic patient self-management concept developed in the Asheville Project.”
After owning an independent pharmacy for many years, Cohen moved into the corporate sector as director of pharmacy for Dominick’s Finer Foods, a division of Safeway, where he held the position of chief pharmacy officer for the supermarket chain—with 91 pharmacies in the Chicago area—with pharmacy sales of $145 million annually.
Among his many awards, Cohen is also a past recipient of the 2007 LittleJohn Award, presented by Midwestern University, and the Chicago College of Pharmacy Alumnus of The Year in 2002.
Celgene to acquire Pharmion for $72/share
SUMMIT, N.J. Celgene and Pharmion have announced a merger agreement, under which Celgene has agreed to acquire Pharmion. Celgene will acquire all of Pharmion’s outstanding shares of common stock for $72 per share payable in cash and share of Celgene common stock.
Under the agreement, Celgene will acquire the rights to three popular Pharmion oncology drugs: Revlimid, Thalomid, and Vidaza. Thalmoid and Revlimid are used to treat patients with multiple myeloma. Vidaza is used to treat myelodysplastic syndromes.
“The acquisition of Pharmion is an exceptional strategic fit that will expand our role as a leader in hematology and oncology,” said Sol Barer, chairman and chief executive officer of Celgene Corporation. “Our combined global infrastructure will leverage the therapeutic and commercial potential of Pharmion’s products, particularly Vidaza, which has the potential to become a major global therapy. By bringing together the talents and resources of both companies, we move closer to our vision of becoming a leading hematology and oncology company in the world, expanding our industry leading programs for safety, access and patient support.”
RxHub introduces Rx 4 Success e-prescribing program
ST. PAUL, Minn. RxHub, a company that keeps track of patient-specific medication history and pharmacy benefit information, has announced a new product for e-prescribing, the Rx 4 Success.
The new program was developed to target four main areas of e-prescribing: utilization of Centers for Medicaid and Medicare Services approved ePrescribing transactions including eligibility, formulary and benefits, and medication history. The program will also integrate true electronic delivery of prescriptions to retail and mail order pharmacies. It will also keep consistent rules-based applications of clinical decision support content and formulate transactional data to support the development of outcomes based on pay-for-performance programs.
“We are extremely proud to be associated with our growing roster of partners which includes many of the healthcare industry’s foremost technology innovators,” stated Doug Johnson, vice president of business development for technology partners at RxHub. “Their collective vision not only helped shape Rx 4 Success but provides the foundation for ongoing market driven performance analysis and improvement.”
Rx 4 Success will become a participation requirement for technology partners connected to the RxHub network as of July 31, 2008.